Gland PharmaNSE:GLAND +5.14%84 PEG Ratio is 13.57 as of Jun. 30, 2026, which is 11% below its 10-year median of 15.21. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,125.65 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 346 Drug Manufacturers companies, Gland Pharma ranks worse than 91.33% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Gland Pharma's PEG Ratio or its related term are showing as below:
NSE:GLAND'
s PEG Ratio Range Over the Past 10 Years
Min: 0.95 Med: 15.21 Max: 145.29
Current: 12.91
During the past 9 years, Gland Pharma's highest PEG Ratio was 145.29. The lowest was 0.95. And the median was 15.21.
NSE:GLAND's PEG Ratio is ranked worse than 91.33% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.695
vs NSE:GLAND: 12.91
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Gland Pharma (NSE:GLAND) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Gland Pharma PEG Ratio Related Terms
Gland Pharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for Gland Pharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Gland Pharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Gland Pharma (NSE:GLAND) has a PEG Ratio of 13.57 as of Jun. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Gland Pharma and its competitors. This is 11% below median its historical median of 15.21. Over the past decade, Gland Pharma's PEG Ratio has ranged from 0.95 to 145.29. According to the industry distribution chart, Gland Pharma ranks #316 out of 346 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Gland Pharma's PEG Ratio too high?
Gland Pharma's current PEG Ratio of 13.57 is 11% below median its 10-year median of 15.21. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 145.29. The Drug Manufacturers industry median PEG Ratio is 1.70. Gland Pharma's value of 13.57 is 700.6% above this industry median. Based on the distribution chart, Gland Pharma ranks #316 out of 346 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #316 out of 346 companies for PEG Ratio. This places Gland Pharma in the lower half of its industry. The industry median PEG Ratio is 1.70. Gland Pharma's value of 13.57 is 700.6% above this benchmark. Historically, Gland Pharma's own PEG Ratio has ranged from 0.95 to 145.29 over the past decade. While the company's 10-year median is 15.21 vs. the industry median of 1.70, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current PEG Ratio of 13.57 is 700.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current PEG Ratio is 13.57, which is 11% below median its own 10-year median of 15.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,495.00 — trading 17.4% above its estimated fair value. The current PEG Ratio is 13.57, which is 11% below median its 10-year median of 15.21 and 700.6% above the Drug Manufacturers industry median of 1.70. Gland Pharma's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current PEG Ratio is 13.57 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,495.00 is trading 17.4% above its estimated GF Value™ of ₹2,125.65.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
PEG Ratio: 13.57 (11% below median its 10-year median of 15.21)
GF Value™: ₹2,125.65 vs. price of ₹2,495.00 (17.4% above fair value)
Industry Position: 700.6% above the Drug Manufacturers median (#316 of 346)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
